Zobrazeno 1 - 10
of 173
pro vyhledávání: '"Ln, Shishkina"'
Autor:
As, Zamedyanskaya, Ka, Titova, Aa, Sergeev, As, Kabanov, Le, Bulychev, Do, Galakhova, Ae, Nesterov, Ov, Nosareva, Ln, Shishkina, Oleg Taranov, Vv, Omigov, Ap, Agafonov, An, Sergeev
Publikováno v:
Europe PubMed Central
Studies of the primary cultures of granulocytes, mononuclear, and monocyte-macrophage cells derived from human blood were performed using variola virus (VARV) in the doses of 0.001-0.021 PFU/cell (plaques-forming units per cell). Positive dynamics of
Autor:
Aa, Sergeev, As, Kabanov, Le, Bulychev, Ov, Pyankov, Sa, Bodnev, Do, Galakhova, As, Zamedyanskaya, Ka, Titova, Ln, Shishkina, Ap, Agafonov, An, Sergeev
Publikováno v:
Europe PubMed Central
In experimental study the sensitivity of the Marmota bobak species to the monkeypox virus (MPXV) with the intranasal (i/n) infection was tested. It was demonstrated that 50% of the infective dose (ID50) of the MPXV on external clinical signs of the d
Autor:
As, Kabanov, Aa, Sergeev, Ln, Shishkina, Le, Bulychev, Mo, Skarnovich, Ni, Bormotov, Iankov Ov, P., Oa, Serova, Sa, Bodnev, Ba, Selivanov, Tikhonov AIa, Ap, Agafonov, An, Sergeev
Publikováno v:
Europe PubMed Central
In the experiments using intranasal (i/n) infection of mice with the ectromelia virus (EV) in a dose 10 LD50/head (10 x 50% lethal doselhead) or with the monkaypox virus (MPXV) in a dose 10 ID50/head (10 x 50% infective dose/ head) it was demonstrate
[In vitro and in vivo efficacy of Ingavirin against strains of pandemic influenza virus A(H1N1/09)v]
Autor:
Ln, Shishkina, Ve, Nebol Sin, As, Kabanov, Mo, Skarnovich, Na, Mazurkova, Artemiy Sergeev, Oa, Serova, Ea, Stavskiĭ, Ig, Drozdov
Publikováno v:
Europe PubMed Central
Artemiy Sergeev
Artemiy Sergeev
To study efficacy of Ingavirin in vitro and in vivo against strains of pandemic influenza virus A(H1N1/09)v and influenza virus A(H5N1) and A(H3N2).Changes in hemagglutinating and cytopathic activity of influenza virus strains A(H1N1/09)v, A(H5N1) an
Autor:
Va, Zhukov, Ln, Shishkina, As, Safatov, Aa, Sergeev, Iankov Ov, P., Va, Petrishchenko, Bn, Zaĭtsev, Vs, Toporkov, An, Sergeev, Nesvizhskiĭ IuV, Aa, Vorob Ev
Publikováno v:
Europe PubMed Central
The paper presents results of testing a modified algorithm for predicting virus ID50 values in a host of interest by extrapolation from a model host taking into account immune neutralizing factors and thermal inactivation of the virus. The method was
Autor:
Va, Zhukov, Ln, Shishkina, Aa, Sergeev, Iv, Fankin, Ma, Smetannikova, Iankov Ov, P., Va, Petrishchenko, An, Sergeev, Aa, Vorob Ev
Publikováno v:
Europe PubMed Central
To predict a potential value of a viral ID50 for a macro-organism of interest (e.g. humans), it is necessary to determine in vitro two parameters of the interaction of the virus with susceptible cells of the host, i.e. the probability of the virus' p
Autor:
Ma, Smetannikova, Ln, Shishkina, Va, Zhukov, Iv, Fankin, Aa, Sergeev, Mo, Skarnovich, Iankov Ov, P., Va, Petrishchenko, Vn, Bondarenko, An, Sergeev
Publikováno v:
Europe PubMed Central
The results of the study showed that subcutaneous kenalog (Kn) lowered the resistance of mice to influenza virus (InV), as was seen by a decrease in 50% lethal dose and an increase in the degree of pulmonary tissue lesion, and the susceptibility of t
Autor:
Iv, Pliasunov, An, Sergeev, Aa, Sergeev, Va, Petrishchenko, Ln, Shishkina, Vv, Generalov, As, Safatov, Ls, Sandakhchiev, Vv, Udut, Sa, Mel Nikov, Vn, Podkuĭko
Publikováno v:
Europe PubMed Central
Clinical trials of oral live recombinant embryonic variola and hepatitis B bivaccine as tablets (Revax-BT) were performed. When volunteers were prevaccinated with oral variola vaccine first in a small dose and, 7, 14, 30, 90, and 180 days later, in a
Autor:
Aa, Sergeev, An, Sergeev, Va, Petrishchenko, Ln, Shishkina, Gv, Kochneva, Va, Zhukov, Nk, Evtin, Iankov Ov, P., Ls, Sandakhchiev, La, Akinfeeva, Vv, Udut, Sherstoboev EIu, Ed, Gol Dberg, Sa, Mel Nikov, Vn, Podkuĭko, Va, Maksimov
Publikováno v:
Europe PubMed Central
The reactogenicity of the embryonic live recombinant variola and hepatitis B bivaccine as tablets (Revax-BT) as well as its safety and immunogenicity were evaluated in clinical trials made in volunteers who had previously immunized or not with variol
Autor:
Va, Zhukov, As, Safatov, Iankov Ov, P., Vs, Toporkov, Aa, Sergeev, Sa, Kiselev, Va, Iashin, Nm, Beliaev, Ei, Riabchikova, Av, Zhukov, Ln, Shishkina, Aa, Medvedev, Va, Petrishchenko, An, Sergeev, Aa, Vorob Ev
Publikováno v:
Europe PubMed Central
A setup for the generation and studies of mono-disperse microbiological aerosols is described in the paper. Coefficients of 3 microm aerosol deposition in the respiratory tract of mice and rats were refined by using the above setup. The probability o